Mumbai, Mar 24: Zydus Lifesciences on Friday said that it has received final approval for Doxepin Hydrochloride Capsules USP, 150 mg from the United States Food and Drug Administration (USFDA).
Doxepin Hydrochloride capsule treats mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level.
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Doxepin Hydrochloride Capsules USP, 150 mg had annual sales of USD 2.11 mn in the United States (IQVIA MAT Jan. 2023).
(UNI)
Follow our WhatsApp channel
